What Is Shuttle Pharmaceuticals Holding (SHPH) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Shuttle Pharmaceuticals Holding's intrinsic value is estimated at $2.65, suggesting the stock is overvalued at its current price of $3.65. With 7 out of 9 models flagging downside (-27.4% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +120.5% (fair value: $8.05), while Sentiment SOTP is the most conservative at -97.8% ($0.08). The spread between these extremes — +218.4% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About SHPH?
9 of 13 models are currently active for SHPH. Of these, 2 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates SHPH's intrinsic value at $3.22, implying -11.8% downside from the current price. See which stocks rank higher →
How Does SHPH Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, SHPH ranks #377 by Quality of Company score. CirclFi's QOC score of 3.4/10 evaluates 32 fundamental signals. A score of 3.4 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Shuttle Pharmaceuticals Holding competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is SHPH a Value Trap?
CirclFi's Value Trap algorithm assigns SHPH a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Shuttle Pharmaceuticals Holding. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Shuttle Pharmaceuticals Holding is rated at 3.4/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.
The gap between the most bullish and bearish model spans +218.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SHPH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SHPH's 9 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad